These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34434428)

  • 1. Phantom Shocks Associated With a Wearable Cardioverter Defibrillator.
    Delle Donna P; Petrovic L; Nasir U; Ahmed A; Suero-Abreu GA
    J Med Cases; 2021 Feb; 12(2):49-53. PubMed ID: 34434428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.
    Epstein AE; Abraham WT; Bianco NR; Kern KB; Mirro M; Rao SV; Rhee EK; Solomon SD; Szymkiewicz SJ
    J Am Coll Cardiol; 2013 Nov; 62(21):2000-2007. PubMed ID: 23916930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of the wearable cardioverter defibrillator in patients with explanted ICD.
    Kaspar G; Sanam K; Gholkar G; Bianco NR; Szymkiewicz S; Shah D
    Int J Cardiol; 2018 Dec; 272():179-184. PubMed ID: 30121177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
    Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
    J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients.
    Erath JW; Vamos M; Sirat AS; Hohnloser SH
    Clin Res Cardiol; 2017 Apr; 106(4):300-306. PubMed ID: 27888304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator.
    Tanawuttiwat T; Garisto JD; Salow A; Glad JM; Szymkiewicz S; Saltzman HE; Kutalek SP; Carrillo RG
    Pacing Clin Electrophysiol; 2014 May; 37(5):562-8. PubMed ID: 24762055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The wearable cardioverter-defibrillator vest: Indications and ongoing questions.
    Sandhu U; Rajyaguru C; Cheung CC; Morin DP; Lee BK
    Prog Cardiovasc Dis; 2019; 62(3):256-264. PubMed ID: 31077726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.
    Andresen H; Sasko B; Patschan D; Pagonas N; Ritter O
    J Med Case Rep; 2021 May; 15(1):243. PubMed ID: 33993888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wearable Cardioverter Defibrillator: an Early Single Centre Australian Experience. Some Pitfalls and Caveats for Use.
    Bhaskaran A; Bartlett M; Kovoor P; Davis LM
    Heart Lung Circ; 2016 Feb; 25(2):155-9. PubMed ID: 26361817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort.
    Zylla MM; Hillmann HAK; Proctor T; Kieser M; Scholz E; Zitron E; Katus HA; Thomas D
    Heart Vessels; 2018 Nov; 33(11):1390-1402. PubMed ID: 29721674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the wearable cardioverter defibrillator in clinical practice.
    Chung MK
    Cardiol Clin; 2014 May; 32(2):253-70. PubMed ID: 24793801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wearable Cardioverter-defibrillators for the Prevention of Sudden Cardiac Death: A Meta-analysis.
    Nguyen E; Weeda ER; Kohn CG; D'Souza BA; Russo AM; Noreika S; Coleman CI
    J Innov Card Rhythm Manag; 2018 May; 9(5):3151-3162. PubMed ID: 32477809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.
    Pires LA; Lehmann MH; Steinman RT; Baga JJ; Schuger CD
    J Am Coll Cardiol; 1999 Jan; 33(1):24-32. PubMed ID: 9935004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with wearable cardioverter defibrillators at a tertiary electrophysiology program.
    Bossory L; Schubert S; Afzal MR; Weiss R; Tyler J; Kalbfleisch S; Augostini R; Hummel J; Okabe T; Daoud EG; Houmsse M
    Pacing Clin Electrophysiol; 2018 Nov; 41(11):1491-1494. PubMed ID: 30191582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.